Want to see IL:INCR full AI Analyst Report?
Top Page
Intercure
(TASE:INCR)
Select Model
Select Model
Rating:59Neutral
Price Target:
1,797.00
▲(4.48% Upside)
Action:Reiterated
Date:08/26/26
The score is driven by a mid-range financial profile (revenue and cash flow rebound but continued losses) and solid technical strength (price above key moving averages with positive momentum). These positives are tempered by weak valuation signals due to negative earnings and the lack of dividend support.
Positive Factors
Revenue Recovery
The return to revenue growth indicates recovering demand and improving commercial traction across InterCure’s medical cannabis portfolio, distribution network and dispensing channels. Sustaining this trend could improve operating leverage over time.
Negative Factors
Persistent Net Losses
InterCure has not yet converted revenue recovery into sustainable profitability. Continued net losses limit internally generated capital, increase execution risk and leave the business more exposed if demand or product margins weaken.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Recovery
The return to revenue growth indicates recovering demand and improving commercial traction across InterCure’s medical cannabis portfolio, distribution network and dispensing channels. Sustaining this trend could improve operating leverage over time.
Read all positive factors
Intercure (INCR) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪196.88M
Dividend YieldN/A
Average Volume (3M)50.50K
Price to Earnings (P/E)―
Beta (1Y)0.52
Revenue GrowthN/A
EPS GrowthN/A
CountryIL
Employees285
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-3.55
Shares Outstanding11,845,711
10 Day Avg. Volume56,256
30 Day Avg. Volume50,500
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.46
Price to Sales (P/S)0.68
P/FCF Ratio13.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Intercure Business Overview & Revenue Model
Company Description
InterCure Ltd., alongside its affiliated companies, is actively involved in the medical cannabis industry, operating both domestically in Israel and internationally. Their activities encompass the entire spectrum from research and cultivation to p...
How the Company Makes Money
InterCure primarily makes money by selling medical cannabis products and related cannabis-based wellness products in Israel. Key revenue streams include: (1) sales of medical cannabis products to patients via retail/dispensing channels, including ...
Intercure Financial Statement Overview
Summary
Income Statement
42
Neutral
Balance Sheet
58
Neutral
Cash Flow
62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 270.20M | 238.84M | 355.55M | 388.68M | 219.68M |
| Gross Profit | 33.18M | 30.23M | 105.09M | 155.08M | 91.13M |
| EBITDA | -7.29M | -51.31M | -23.90M | 70.23M | 31.17M |
| Net Income | -35.71M | -67.80M | -61.96M | 44.82M | 4.69M |
Balance Sheet | |||||
| Total Assets | 690.55M | 762.57M | 786.61M | 958.01M | 686.32M |
| Cash, Cash Equivalents and Short-Term Investments | 46.67M | 78.65M | 101.33M | 232.79M | 196.55M |
| Total Debt | 183.01M | 211.40M | 195.68M | 255.16M | 108.91M |
| Total Liabilities | 294.19M | 364.90M | 329.55M | 436.53M | 227.13M |
| Stockholders Equity | 396.52M | 396.97M | 455.11M | 501.31M | 448.03M |
Cash Flow | |||||
| Free Cash Flow | 13.29M | -71.30M | -56.25M | 31.52M | 10.99M |
| Operating Cash Flow | 16.84M | -66.93M | -53.63M | 51.27M | 25.02M |
| Investing Cash Flow | -1.99M | 17.69M | 4.77M | -142.50M | -65.21M |
| Financing Cash Flow | -46.66M | 26.45M | -82.89M | 120.45M | 197.94M |
Intercure Peers Comparison
UnderperformOutperform
Sector (55)
IL:INCR
Intercure
1,662.00
-1,106.00
-39.96%
IL:TGTR
Together
205.00
-175.90
-46.18%
IL:CNZN.M
Canzon-M
88.00
-68.40
-43.73%
IL:SEMG
Seach Medical
265.40
10.84
4.26%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.